Company signals · Biotech & Pharma
BioMarin Pharmaceutical
1 signal in the current window, with MitchelLake's leadership read on each.
Last updated
Market context: The wider read — a Talent Market Index of 100.4 (Neutral), down 1.1 month-on-month — shows Americas signal flow easing (-1.8pts).
BioMarin Pharmaceutical: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 25 tracked companies.
Signals at BioMarin Pharmaceutical
BioMarin Pharmaceutical signals in the last 90 days
1 public signal observed since 20 May 2026, by type.
MitchelLake in this thematic
More signals across Biotech & Pharma
Product Launch · Americas
Bristol Myers Squibb →FDA granted accelerated approval for iberdomide (marketed as Zenbexus), a multiple myeloma treatment for relapsed or refractory patients.
Product Launch · Americas
Amgen →Amgen is advancing MariTide, a monthly weight-loss injection, through 6 Phase 3 trials as a direct competitor to Eli Lilly and Novo Nordisk's weekly GLP-1 drugs. The product is positioned to enter the market with a convenience advantage.
Product Launch · Americas
Boehringer Ingelheim →Boehringer Ingelheim reported first-half 2026 sales growth of 16.2% (EUR 15.8 billion), driven by strong U.S. performance including increased demand for JARDIANCE® and successful new product launches.
Product Launch · Americas
Neurocrine Biosciences →Neurocrine initiated Phase 2 open-label study of CRENESSITY (crinecerfont) in U.S. infants and toddlers (3 months to under 4 years) with classic congenital adrenal hyperplasia, with concurrent EU trial at target enrollment. Moving toward supplemental U.S. filing to extend indication into pediatric population with no approved therapies.
Product Launch · Americas
Celltrion →Celltrion's Truxima (rituximab biosimilar) received FDA interchangeability status—the first rituximab biosimilar to achieve this designation in the United States. This enables automatic substitution without new prescriptions and grants exclusivity protection.
Product Launch · Americas
Bota Biosciences →Bota Biosciences released Biology Protocol Language (BPL) and BPL-COGEN, a compiler-verified protocol language and generation pipeline for AI-driven biomanufacturing, announced on bioRxiv.
Where BioMarin Pharmaceutical's market lands in our work
- Enterprise Innovation & Transformation →
A launch is the output of a product and engineering leadership layer built before it.
- Executive Search — Americas →
Our Americas practice runs the searches behind signals like this one.
Intelligence powered by Autonodal ↗
Nearby in the record